- Q2 2024 Rigel Pharmaceuticals Inc Earnings Call TranscriptAug 06, 2024$9.33 (+6.02%)Earnings
- Q1 2024 Rigel Pharmaceuticals Inc Earnings Call TranscriptMay 07, 2024$11.9 (-2.46%)Earnings
- Q4 2023 Rigel Pharmaceuticals Inc Earnings Call TranscriptMar 05, 2024$14.8 (+0.68%)Earnings
- Rigel Pharmaceuticals Inc at JPMorgan Healthcare Conference TranscriptJan 11, 2024
- Q3 2023 Rigel Pharmaceuticals Inc Earnings Call TranscriptNov 07, 2023$8.71 (+3.51%)Earnings
- Rigel Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference TranscriptSep 27, 2023
- Q2 2023 Rigel Pharmaceuticals Inc Earnings Call TranscriptAug 01, 2023$13.3 (-3.62%)Earnings
- Rigel Pharmaceuticals Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Q1 2023 Rigel Pharmaceuticals Inc Earnings Call TranscriptMay 02, 2023$11.4 (-4.20%)Earnings
- Q4 2022 Rigel Pharmaceuticals Inc Earnings Call TranscriptMar 07, 2023$14.7 (-3.29%)Earnings
- Rigel Pharmaceuticals Inc To Discuss The FDA Approval of REZLIDHIA Call TranscriptDec 01, 2022
- Q3 2022 Rigel Pharmaceuticals Inc Earnings Call TranscriptNov 03, 2022$7.26 (+3.23%)Earnings
- Q2 2022 Rigel Pharmaceuticals Inc Earnings Call TranscriptAug 02, 2022$13 (+7.44%)Earnings
- Rigel Pharmaceuticals Inc to Discuss FORWARD Study Results TranscriptJun 08, 2022
- Q1 2022 Rigel Pharmaceuticals Inc Earnings Call TranscriptMay 03, 2022$24.8 (+0.81%)Earnings
- Q4 2021 Rigel Pharmaceuticals Inc Earnings Call TranscriptMar 01, 2022$25.1Earnings
- Rigel Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 12, 2022
- Q3 2021 Rigel Pharmaceuticals Inc Earnings Call TranscriptNov 02, 2021$35.7 (+0.85%)Earnings
- Rigel Pharmaceuticals Inc at Citi BioPharma Conference (Virtual) TranscriptSep 10, 2021
- Q2 2021 Rigel Pharmaceuticals Inc Earnings Call TranscriptAug 03, 2021$37.8 (-5.97%)Earnings
- Rigel Pharmaceuticals Inc Annual Shareholders Meeting TranscriptMay 18, 2021
- Q1 2021 Rigel Pharmaceuticals Inc Earnings Call TranscriptMay 05, 2021$34.7 (+0.87%)Earnings
- Rigel Pharmaceuticals Inc Positive Topline Data Shows Fostamatinib Meets Primary Endpoint of Safety in Phase 2 Clinical Trial in Hospitalized Patients with COVID-19 -Corporate Call TranscriptApr 13, 2021
- Q4 2020 Rigel Pharmaceuticals Inc Earnings Call TranscriptMar 02, 2021$43.05 (-3.69%)Earnings
- Rigel Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) TranscriptJan 14, 2021
- Q3 2020 Rigel Pharmaceuticals Inc Earnings Call TranscriptNov 05, 2020$27.4 (+1.48%)Earnings
- Rigel Pharmaceuticals Inc at Citi BioPharma Conference (Virtual)- Panel: State of Play for COVID-19 Therapeutics TranscriptSep 09, 2020
- Q2 2020 Rigel Pharmaceuticals Inc Earnings Call TranscriptAug 04, 2020$24.6 (+1.23%)Earnings
- Rigel Pharmaceuticals Inc Annual Shareholders Meeting TranscriptMay 14, 2020
- Q1 2020 Rigel Pharmaceuticals Inc Earnings Call TranscriptMay 05, 2020$19.6 (+5.95%)Earnings
- Q4 2019 Rigel Pharmaceuticals Inc Earnings Call TranscriptFeb 27, 2020$20.4 (-5.99%)Earnings
- Rigel Pharmaceuticals Inc at JPMorgan Healthcare Conference TranscriptJan 16, 2020
- Q3 2019 Rigel Pharmaceuticals Inc Earnings Call TranscriptNov 05, 2019$21.7 (+0.93%)Earnings
- Rigel Pharmaceuticals Inc Investor and Analyst Call TranscriptOct 23, 2019
- Editas Medicine Inc, Apellis Pharmaceuticals Inc and Rigel Pharmaceuticals Inc at Citi Biotech Conference TranscriptSep 05, 2019
- Q2 2019 Rigel Pharmaceuticals Inc Earnings Call TranscriptAug 06, 2019$21.7 (+3.33%)Earnings
- Q1 2019 Rigel Pharmaceuticals Inc Earnings Call TranscriptMay 07, 2019$23.2 (-2.52%)Earnings
- Q4 2018 Rigel Pharmaceuticals Inc Earnings Call TranscriptFeb 28, 2019$21.9 (-3.10%)Earnings
Rigel Pharmaceuticals Inc Positive Topline Data Shows Fostamatinib Meets Primary Endpoint of Safety in Phase 2 Clinical Trial in Hospitalized Patients with COVID-19 -Corporate Call Transcript
Greetings and welcome to Rigel Pharmaceuticals Fostamatinib in COVID-19 Phase II Trial Results Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.
It is now my pleasure to introduce our first speaker, Dolly Vance, who is Rigel's Executive Vice President, Corporate Affairs and General Counsel. Thank you. Ms. Vance, you may begin.
Welcome to our fostamatinib in COVID-19 Phase II top line results conference call.
Earlier today, the company issued a press release providing a summary of the top line data, which can be viewed, along with the accompanying slides through this presentation, in the News and Events section of our Investor Relations page on our website at www.rigel.com.
As a reminder, during today's call, we may make forward-looking statements regarding our plans and timing for regulatory and product
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)